Aim Acquisition Enhances Inspirata’s R&D in Artificial Intelligence and Natural Language Processing
Cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced today that it has acquired Toronto-based Artificial Intelligence in Medicine, Inc. (AIM). AIM has spent more than 30 years developing and commercializing tools that leverage Artificial Intelligence (AI) and Natural Language Processing (NLP) to extract cancer related information and data from clinical documents, such as pathology reports, molecular testing reports, treatment plans and clinician’s notes.
NLP is the application of computer science, linguistics and AI to interpret narrative text. More than 65 percent of clinical data is in the form of unstructured text in healthcare documents stored in electronic medical records and laboratory information systems. Without the use of NLP and other AI techniques to make this data available efficiently and accurately for analysis and reporting, cancer centers must resort to manual data abstraction, which is expensive, time consuming and error prone.
Once extracted from source documents and files, the discrete cancer data, which includes specific tumor properties, such as size, margins, nodal involvement, stage, grade, laterality as well as patient demographics and other information, can be stored and readily searched to create specific datasets needed for analysis and reporting. This includes the reports that U.S. cancer centers must provide to their state National Program of Cancer Registries (NPCR) as well as the National Cancer Institute’s Surveillance, Epidemiology and End Results Program (SEER). These federally mandated registries are responsible for reporting to the Center for Disease Control (CDC) all invasive cancers diagnosed in their respective states. In addition to Cancer Registry reporting requirements, cancer centers need to be able to employ cancer data for population health studies, to evaluate quality metrics, identify patient cohorts for clinical trials and cancer research, as well as for a wide range of other applications.
“The acquisition of AIM is extremely strategic for Inspirata because it enables us to bolster our own NLP development efforts by leveraging AIM’s 30+ years in this field,” says Inspirata CEO Satish Sanan. “AIM has an outstanding group of NLP engineers and data scientists as well as a solid leadership team that will remain in place and continue to focus on R&D and business growth. This acquisition also establishes a solid footprint for Inspirata in Canada, allowing us to better grow our customer base to our north.”
“After spending the last 34 years building AIM into a leader in creating technologies to improve cancer care, I am confident that I am leaving behind a great legacy and turning the future of AIM over to an organization that is equally committed to the same goals we’ve always had,” says AIM founder and CEO, Peter Brueckner. “Continuity is so very important and that is why our current Vice President of Engineering, Jack Golabek, will become the new CEO of AIM, reporting directly to Satish. I am confident that what we have built over the last three decades will flourish within Inspirata and that AIM’s technology will form the foundation for a suite of superior cancer informatics products.”
This article has been republished from materials provided by Inspirata. Note: material may have been edited for length and content. For further information, please contact the cited source.
Organizations looking to benefit from the artificial intelligence (AI) revolution should be cautious about putting all their eggs in one basket, a study published in Nature Machine Intelligence has found. Researchers found that contrary to conventional wisdom, there can be no exact method for deciding whether a given problem may be successfully solved by machine learning tools.READ MORE